Pivmecillinam: Brands, Price & Uses in Bangladesh

Pivmecillinam is a beta-lactam antibiotic (amidinopenicillin class) indicated for the treatment of specific bacterial infections. Its indications, classified by strength of evidence, are as follows:

Established / Approved Use

• Uncomplicated lower urinary tract infection (acute cystitis): Pivmecillinam is indicated for the treatment of uncomplicated urinary tract infections (acute cystitis) in adult women caused by susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus. It is not indicated for pyelonephritis or complicated UTI.

Guideline-Supported Use

• Several international UTI treatment guidelines list Pivmecillinam as a first-line or alternative first-line option for uncomplicated cystitis in non-pregnant and, in some national guidelines, pregnant women, owing to its narrow-spectrum activity against common uropathogens and its distinguishing mechanism of action (preferential binding to penicillin-binding protein 2, PBP2) compared with typical penicillins.

Not Established

• Safety and efficacy have not been established for pyelonephritis, complicated UTI, use in men, or use in patients under 18 years of age; Pivmecillinam should not be used for these indications outside specific physician direction.

Pivmecillinam should only be used for infections proven or strongly suspected to be caused by susceptible bacteria, as prescribed by a physician.

Adult Dosage (Uncomplicated Cystitis)

Pivmecillinam tablets may be taken with or without food. Tablets should be swallowed whole with a full glass of water.

Pediatric Dosage

Safety and efficacy of Pivmecillinam have not been established in patients under 18 years of age; a pediatric dosing regimen is not established for this formulation in this market. See Use in Special Populations.

Renal Impairment

Pivmecillinam (as mecillinam) is eliminated mainly by the kidneys. No formal dose-adjustment schedule has been established; use with caution in patients with significant renal impairment, and consider an extended dosing interval in patients with severe renal impairment (creatinine clearance below 30 mL/min), at the physician's discretion.

Hepatic Impairment

Use with caution in patients with severe hepatic impairment (see Contraindications and Precautions regarding carnitine-related hepatic effects); no specific dose adjustment has been established.

Antibiotic Stewardship

Take Pivmecillinam exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice. Completing the full prescribed course, even if symptoms improve early, helps prevent recurrence and the development of antibiotic-resistant bacteria.

Most patients tolerate Pivmecillinam well. Reported adverse effects include:

Common

• Nausea
• Diarrhea
• Headache
• Vulvovaginal candidiasis (vaginal yeast infection)

Less Common / Uncommon

• Skin rash
• Hypersensitivity reactions (see Precautions and Warnings)
• Abdominal discomfort, vomiting

Rare but Clinically Important

• Carnitine deficiency: With prolonged or frequently repeated courses of Pivmecillinam, depletion of body carnitine stores (from the pivalic acid component) can occur, rarely producing symptoms of muscle weakness or metabolic disturbance. This risk is low with typical short-course (3-7 day) UTI treatment but rises with extended or recurrent use.
• Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) — rare, see Precautions and Warnings.
• Clostridioides difficile-associated diarrhea, ranging from mild to severe colitis.

Contact your physician if you experience severe or persistent side effects while taking Pivmecillinam.